文献速递肝肾功能剂量调整特殊人群用药

培氟替尼在类风湿关节炎患者中的群体药代动力学分析

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-01

该分析基于98名健康志愿者和989名类风湿关节炎患者的群体药代动力学数据,构建了培氟替尼的二室模型,发现估算肾小球滤过率和淋巴细胞计数是清除率的显著协变量,但变化幅度无临床相关性,提示无需调整剂量。

要点

  • eGFR和淋巴细胞计数影响培氟替尼清除率,但变化幅度不具临床相关性。
  • 严重肾损伤患者AUC较参考eGFR患者增加1.35倍,但无需剂量调整。
  • 群体药代动力学模型可为RA患者用药提供参考,支持固定剂量方案。

核心结论

  • eGFR和淋巴细胞计数是培氟替尼清除率的显著协变量,但变化幅度无临床相关性,无需剂量调整。

研究设计与样本

  • 群体药代动力学分析,纳入98名健康志愿者的2464个观测值和989名RA患者的4919个观测值,使用NONMEM构建非线性混合效应模型。

主要发现

  • 最终模型为二室模型,含序贯零级和一级吸收及滞后时间。
  • eGFR和淋巴细胞计数对表观总清除率有显著影响,清除率为91.7 L/h(相对标准误2.3%)。
  • 淋巴细胞计数最低500和最高4600×10^6/L时,清除率平均变化分别为12.3%和-10.7%。
  • eGFR最低36.4和最高188 mL/min/1.73m^2时,清除率平均变化分别为-17.8%和16.7%。
  • 严重肾损伤患者(eGFR 22.5 mL/min/1.73m^2)的AUC较参考eGFR(91.5 mL/min/1.73m^2)患者增加1.35倍。

临床怎么用

  • 基于当前分析,培氟替尼在RA患者中无需根据eGFR或淋巴细胞计数调整剂量。

局限性

  • 未报告模型验证、预测性能评估或外部验证结果。
  • 未报告协变量对暴露量影响的临床相关性阈值。
  • 未报告严重肾损伤患者的实际剂量调整建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To analyse the population pharmacokinetics (PK) of peficitinib in patients with rheumatoid arthritis (RA) and assess the potential PK covariates to identify the requirement for dose adjustment in RA patients. METHODS: The analysis incorporated 2464 observations from 98 healthy volunteers and 4919 observations from 989 RA patients. A population PK model for peficitinib in RA patients was constructed by a nonlinear mixed effect model using NONMEM with prior information from a healthy volunteer model. RESULTS: A 2-compartment model with sequential zero- and first-order absorption and lag time was constructed for RA patients. Covariate exploration in the RA patient model revealed that estimated glomerular filtration rate (eGFR) and lymphocyte count had a significant effect on apparent total systemic clearance (CL), which was 91.7 L/h (2.3% relative standard error). Compared with the mean population CL, the model predicted mean changes in CL of 12.3 and -10.7% in patients with observed minimum and maximum lymphocyte count of 500 and 4600 106 /L, respectively, and mean changes in CL of -17.8 and 16.7% in patients with minimum and maximum eGFR of 36.4 and 188 mL/min/1.73m2 , respectively. The simulated population mean area under plasma concentration-time curve for 24 hours after dosing showed a 1.35-fold increase in patients with severe renal impairment (eGFR 22.5 mL/min/1.73m2 ) compared with patients with reference eGFR (91.5 mL/min/1.73m2 ). CONCLUSION: The population PK model identified eGFR and lymphocyte count as covariates for CL. The magnitude of changes was not considered clinically relevant, indicating no requirement for dose adjustment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Toyoshima J, Shibata M, Kaibara A, et al. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2020. PMID: 33068028. doi:10.1111/bcp.14605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。